Novartis: Sjogren's Syndrome trials
The registry lists 15 Sjogren's Syndrome studies with Novartis as lead sponsor. 3 are open to participants now and 7 have results posted.
Phase 1 1Phase 2 10Phase 3 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's DiseaseRecruitingNCT07737743Phase 2
- Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom BurdenRecruitingNCT07621809Phase 3
- Managed Access Programs for VAY736, IanalumabAvailableNCT07244289
- A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)TerminatedNCT04988087Phase 2Results posted
- Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's SyndromeCompletedNCT04541589Phase 2Results posted
- A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye DiseaseCompletedNCT04391894Phase 2Results posted
- A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's SyndromeTerminatedNCT04035668Phase 2Results posted
- Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's SyndromeCompletedNCT03905525Phase 2Results posted
- Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)CompletedNCT02962895Phase 2Results posted
- Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's SyndromeCompletedNCT02291029Phase 2Results posted
- A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.Active, not recruitingNCT05985915Phase 3
- Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeCompletedNCT05350072Phase 3
- Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeActive, not recruitingNCT05349214Phase 3
- Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.CompletedNCT05124925Phase 2
- Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's SyndromeWithdrawnNCT02495129Phase 1/2